JP2007508272A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007508272A5 JP2007508272A5 JP2006530155A JP2006530155A JP2007508272A5 JP 2007508272 A5 JP2007508272 A5 JP 2007508272A5 JP 2006530155 A JP2006530155 A JP 2006530155A JP 2006530155 A JP2006530155 A JP 2006530155A JP 2007508272 A5 JP2007508272 A5 JP 2007508272A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- spp
- polypeptide
- combined preparation
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002163 immunogen Effects 0.000 claims 24
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- 239000002671 adjuvant Substances 0.000 claims 11
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 9
- 229930182490 saponin Natural products 0.000 claims 9
- 150000007949 saponins Chemical class 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 102100022144 Achaete-scute homolog 2 Human genes 0.000 claims 3
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims 3
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims 3
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 3
- -1 CASB616 Proteins 0.000 claims 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims 3
- 101000901109 Homo sapiens Achaete-scute homolog 2 Proteins 0.000 claims 3
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 3
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims 3
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 claims 3
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 3
- 102100034872 Kallikrein-4 Human genes 0.000 claims 3
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims 3
- 102100034256 Mucin-1 Human genes 0.000 claims 3
- 108010008707 Mucin-1 Proteins 0.000 claims 3
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 claims 3
- 102000036673 PRAME Human genes 0.000 claims 3
- 108060006580 PRAME Proteins 0.000 claims 3
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 3
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 claims 3
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 3
- 102100037253 Solute carrier family 45 member 3 Human genes 0.000 claims 3
- 108010002687 Survivin Proteins 0.000 claims 3
- 108010017842 Telomerase Proteins 0.000 claims 3
- 102000003425 Tyrosinase Human genes 0.000 claims 3
- 108060008724 Tyrosinase Proteins 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 108010024383 kallikrein 4 Proteins 0.000 claims 3
- 239000007764 o/w emulsion Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 108010079891 prostein Proteins 0.000 claims 3
- 235000002020 sage Nutrition 0.000 claims 3
- 241001647372 Chlamydia pneumoniae Species 0.000 claims 2
- 241000588722 Escherichia Species 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 241000224016 Plasmodium Species 0.000 claims 2
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 235000010384 tocopherol Nutrition 0.000 claims 2
- 229960001295 tocopherol Drugs 0.000 claims 2
- 229930003799 tocopherol Natural products 0.000 claims 2
- 239000011732 tocopherol Substances 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 241000588807 Bordetella Species 0.000 claims 1
- 241000589968 Borrelia Species 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 241000606153 Chlamydia trachomatis Species 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 241000589989 Helicobacter Species 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 241000724675 Hepatitis E virus Species 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 241000186781 Listeria Species 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241000588621 Moraxella Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 241000588653 Neisseria Species 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 241000223960 Plasmodium falciparum Species 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
- 241000223996 Toxoplasma Species 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 1
- 229940038705 chlamydia trachomatis Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 231100000249 enterotoxic Toxicity 0.000 claims 1
- 230000002242 enterotoxic effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229940031439 squalene Drugs 0.000 claims 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0323965.4A GB0323965D0 (en) | 2003-10-13 | 2003-10-13 | Immunogenic compositions |
| PCT/EP2004/011620 WO2005039634A1 (en) | 2003-10-13 | 2004-10-11 | Vaccine compositions comprising an interleukin 18 and saponin adjuvant system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007508272A JP2007508272A (ja) | 2007-04-05 |
| JP2007508272A5 true JP2007508272A5 (enExample) | 2007-07-26 |
Family
ID=29559205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006530155A Pending JP2007508272A (ja) | 2003-10-13 | 2004-10-11 | インターロイキン１８およびサポニンアジュバント系を含むワクチン組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070212329A1 (enExample) |
| EP (1) | EP1687025A1 (enExample) |
| JP (1) | JP2007508272A (enExample) |
| KR (1) | KR20070054136A (enExample) |
| CN (1) | CN1889977A (enExample) |
| AU (1) | AU2004283457A1 (enExample) |
| BR (1) | BRPI0415304A (enExample) |
| CA (1) | CA2541695A1 (enExample) |
| CO (1) | CO5700790A2 (enExample) |
| GB (1) | GB0323965D0 (enExample) |
| IL (1) | IL174544A0 (enExample) |
| IS (1) | IS8374A (enExample) |
| MA (1) | MA28149A1 (enExample) |
| NO (1) | NO20061912L (enExample) |
| RU (1) | RU2006111847A (enExample) |
| WO (1) | WO2005039634A1 (enExample) |
| ZA (1) | ZA200602950B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120011898A (ko) * | 2000-02-10 | 2012-02-08 | 아보트 러보러터리즈 | 사람 인터류킨-１８에 결합하는 항체 및 이를 제조하고 사용하는 방법 |
| US7524824B2 (en) * | 2003-09-04 | 2009-04-28 | Pacific Arrow Limited | Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
| US7727561B2 (en) | 2001-08-31 | 2010-06-01 | Pacific Arrow Limited | Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
| AU2003259827B2 (en) * | 2002-08-12 | 2008-09-04 | Dynavax Technologies Corporation | Immunomodulatory compositions, methods of making, and methods of use thereof |
| US8614197B2 (en) * | 2003-10-09 | 2013-12-24 | Pacific Arrow Limited | Anti-tumor compounds with angeloyl groups |
| US7514412B2 (en) * | 2003-10-09 | 2009-04-07 | Pacific Arrow Limited | Anticancer biangeloyl saponins |
| US7488753B2 (en) * | 2003-10-09 | 2009-02-10 | Pacific Arrow Limited | Composition comprising triterpene saponins and compounds with angeloyl functional group, methods for preparing same and uses thereof |
| EP1670491B1 (en) * | 2003-10-09 | 2015-07-29 | Pacific Arrow Limited | Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
| US7968684B2 (en) * | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| DE102004022200B4 (de) | 2004-05-05 | 2006-07-20 | Actinium Pharmaceuticals, Inc. | Radium-Target sowie Verfahren zu seiner Herstellung |
| US9382285B2 (en) | 2004-09-07 | 2016-07-05 | Pacific Arrow Limited | Methods and compounds for modulating the secretion or expression of adhesion proteins or angiopoietins of cells |
| US8735558B2 (en) * | 2005-02-14 | 2014-05-27 | Pacific Arrow Limited | Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof |
| US8586719B2 (en) * | 2005-04-27 | 2013-11-19 | Pacific Arrow Limited | Triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents |
| DE102006008023B4 (de) | 2006-02-21 | 2008-05-29 | Actinium Pharmaceuticals, Inc. | Verfahren zum Reinigen von 225Ac aus bestrahlten 226Ra-Targets |
| ES2504522T3 (es) | 2006-09-08 | 2014-10-08 | Actinium Pharmaceuticals Inc. | Método para la purificación de radio a partir de diferentes fuentes |
| EP2129394B1 (en) * | 2007-03-09 | 2012-06-20 | Merck Sharp & Dohme Corp. | Papillomavirus vaccine compositions |
| CN106310293A (zh) * | 2007-09-27 | 2017-01-11 | 免疫疫苗技术有限公司 | 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用 |
| US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| EP2818178A1 (en) | 2008-01-11 | 2014-12-31 | The Government of The United States of America as represented by The Secretary, Department of Health and Human Services | Polypeptide vaccine and vaccination strategy against mycobacterium |
| JP5715051B2 (ja) | 2008-06-05 | 2015-05-07 | イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物 |
| NZ727616A (en) * | 2008-06-27 | 2018-06-29 | Zoetis Services Llc | Novel adjuvant compositions |
| TWI351288B (en) * | 2008-07-04 | 2011-11-01 | Univ Nat Pingtung Sci & Tech | Cpg dna adjuvant in avian vaccines |
| PL2444103T3 (pl) * | 2009-06-19 | 2018-05-30 | Eyegene Inc. | Szczepionka przeciwko rakowi szyjki macicy |
| US20120277308A1 (en) | 2010-07-16 | 2012-11-01 | Pacific Arrow Limited | compounds for treating cancer and other diseases |
| US9434677B2 (en) | 2009-07-16 | 2016-09-06 | Pacific Arrow Limited | Natural and synthetic compounds for treating cancer and other diseases |
| US9499577B2 (en) | 2009-07-16 | 2016-11-22 | Pacific Arrow Limited | Natural and synthetic compounds for treating cancer and other diseases |
| AU2011209399B2 (en) * | 2010-01-27 | 2014-04-10 | Glaxo Group Limited | Modified tuberculosis antigens |
| CN103025351B (zh) * | 2010-05-28 | 2016-08-24 | 佐蒂斯比利时股份有限公司 | 包含胆固醇和作为唯一的佐剂-载剂分子的cpg的疫苗 |
| GB201016471D0 (en) * | 2010-09-30 | 2010-11-17 | Isis Innovation | Viral vector immunogenic compositions |
| RU2482866C2 (ru) * | 2010-10-07 | 2013-05-27 | Общество с ограниченной ответственностью "Аллоферон" | Способ лечения папилломавирусных инфекций, реализуемый через индукцию интерлейкина-18 |
| CN103998058B (zh) | 2011-10-06 | 2021-11-05 | 免疫疫苗技术有限公司 | 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用 |
| GB201205361D0 (en) * | 2012-03-27 | 2012-05-09 | Univ Nottingham Trent | Breast cancer assay |
| AU2014203977B2 (en) * | 2013-01-04 | 2016-11-17 | Obi Pharma, Inc. | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant |
| US10166288B2 (en) | 2014-10-01 | 2019-01-01 | The Trustees Of The University Of Pennsylvania | Vaccines having an antigen and interleukin-21 as an adjuvant |
| US10456459B2 (en) | 2015-07-20 | 2019-10-29 | Zoetis Services Llc | Liposomal adjuvant compositions |
| GB201522329D0 (en) * | 2015-12-17 | 2016-02-03 | Glaxosmithkline Biolog S A And Inst Nat De La Sante Et De La Rech Medicale Inserm And Université Pie | Use of adjuvants for the prevention and/or treatment of autoimmune diseases |
| AU2017351900B2 (en) * | 2016-10-31 | 2020-11-26 | Eyegene Inc. | Composition for enhancing immunity comprising immune modulator and cationic liposome, and use of same |
| CU24534B1 (es) * | 2017-11-06 | 2021-07-02 | Ct Inmunologia Molecular | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
| CN107952069A (zh) * | 2017-11-24 | 2018-04-24 | 长春百克生物科技股份公司 | 重组疫苗及其应用 |
| EP3669890A1 (en) | 2018-12-18 | 2020-06-24 | Croda International PLC | Filamentous nanoparticles having vaccine adjuvant effect |
| TR201907085A2 (tr) | 2019-05-10 | 2020-11-23 | Univ Yeditepe | Parazi̇tleri̇n ve parazi̇tlerden elde edi̇len ekstraselüler vezi̇külleri̇n kanser tedavi̇si̇nde kullanimi |
| BR112022004228A2 (pt) * | 2019-09-09 | 2022-05-31 | Glaxosmithkline Biologicals Sa | Composições imunoterapêuticas |
| WO2021115410A1 (zh) * | 2019-12-13 | 2021-06-17 | 南京远大赛威信生物医药有限公司 | 免疫刺激组合物及其用途 |
| WO2022034555A1 (en) * | 2020-08-13 | 2022-02-17 | Janssen Biopharma, Inc. | Polynucleotide constructs and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA40597C2 (uk) * | 1992-06-25 | 2001-08-15 | Смітклайн Бічем Байолоджікалс С.А. | Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів |
| US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6355256B1 (en) * | 1994-09-30 | 2002-03-12 | Ludwig Institute For Cancer Research | Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof |
| GB9712347D0 (en) * | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| WO1999056775A1 (en) * | 1998-05-07 | 1999-11-11 | Akzo Nobel N.V. | Use of interleukin-18 as vaccine adjuvant |
| US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| EP1187629B1 (en) * | 1999-04-19 | 2004-09-22 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| US6843987B2 (en) * | 2000-02-02 | 2005-01-18 | Schering Corporation | Mammalian cytokines; receptors; related reagents and methods |
| KR20120011898A (ko) * | 2000-02-10 | 2012-02-08 | 아보트 러보러터리즈 | 사람 인터류킨-１８에 결합하는 항체 및 이를 제조하고 사용하는 방법 |
-
2003
- 2003-10-13 GB GBGB0323965.4A patent/GB0323965D0/en not_active Ceased
-
2004
- 2004-10-11 RU RU2006111847/13A patent/RU2006111847A/ru not_active Application Discontinuation
- 2004-10-11 KR KR1020067009283A patent/KR20070054136A/ko not_active Withdrawn
- 2004-10-11 EP EP04790465A patent/EP1687025A1/en not_active Withdrawn
- 2004-10-11 WO PCT/EP2004/011620 patent/WO2005039634A1/en not_active Ceased
- 2004-10-11 CN CNA2004800363071A patent/CN1889977A/zh active Pending
- 2004-10-11 AU AU2004283457A patent/AU2004283457A1/en not_active Abandoned
- 2004-10-11 CA CA002541695A patent/CA2541695A1/en not_active Abandoned
- 2004-10-11 BR BRPI0415304-9A patent/BRPI0415304A/pt not_active Application Discontinuation
- 2004-10-11 US US10/575,838 patent/US20070212329A1/en not_active Abandoned
- 2004-10-11 JP JP2006530155A patent/JP2007508272A/ja active Pending
-
2006
- 2006-03-23 IL IL174544A patent/IL174544A0/en unknown
- 2006-03-27 IS IS8374A patent/IS8374A/is unknown
- 2006-04-07 CO CO06034535A patent/CO5700790A2/es not_active Application Discontinuation
- 2006-04-11 ZA ZA200602950A patent/ZA200602950B/xx unknown
- 2006-04-28 NO NO20061912A patent/NO20061912L/no not_active Application Discontinuation
- 2006-05-04 MA MA29002A patent/MA28149A1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007508272A5 (enExample) | ||
| RU2006111847A (ru) | Вакцинные композиции, содержащие интерлейкин 18 и сапониновую адъювантную систему | |
| JP2007508273A5 (enExample) | ||
| RU2006111849A (ru) | Иммуногенные композиции | |
| Lacaille-Dubois | Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review | |
| O'Hagan et al. | Recent developments in adjuvants for vaccines against infectious diseases | |
| ES2331952T3 (es) | Fraccion de quil a con baja toxicidad y su uso. | |
| Hedayat et al. | Targeting of Toll-like receptors: a decade of progress in combating infectious diseases | |
| O’Hagan | Recent advances in vaccine adjuvants for systemic and mucosal administration | |
| TWI232753B (en) | Adjuvant compositions comprising QS-21,3D-MPL and CpG and vaccine compositions comprising the same | |
| Mäkelä | Vaccines, coming of age after 200 years | |
| Singh et al. | Recent advances in vaccine adjuvants | |
| Weinberger et al. | Vaccines for the elderly | |
| O'Hagan et al. | Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles | |
| RU2004135541A (ru) | Иммуногенные композиции | |
| US20020160011A1 (en) | Adjuvant compositions for vaccines | |
| JP2014520807A5 (enExample) | ||
| JP2004511529A (ja) | 免疫刺激性オリゴヌクレオチドおよびトコールを含むアジュバント組成物 | |
| JP2006506441A5 (enExample) | ||
| Xiang et al. | Promising particle-based vaccines in cancer therapy | |
| Moingeon et al. | Delivery technologies for human vaccines | |
| JP5199026B2 (ja) | 血糖を制御するための医薬組成物及びその方法 | |
| JP5307859B2 (ja) | ワクチン | |
| JP2003530088A5 (enExample) | ||
| JP2004531540A (ja) | Ｈｉｖ抗原並びにｈｓｖ抗原及び／又はｈｐｖ抗原を含む多価ワクチン |